Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2-dependent mechanism.

Ni, Wei-Jian; Zhou, Hong; Lu, Hao; Ma, Nan-Nan; Hou, Bing-Bing; Li, Wei; Kong, Fan-Xu; Yu, Ju-Tao; Hou, Rui; Jin, Juan; Wen, Jia-Gen; Zhang, Tao; Meng, Xiao-Ming

Ni, Wei-Jian; Zhou, Hong; Lu, Hao; Ma, Nan-Nan; Hou, Bing-Bing; Li, Wei; Kong, Fan-Xu; Yu, Ju-Tao; Hou, Rui; Jin, Juan; Wen, Jia-Gen; Zhang, Tao; Meng, Xiao-Ming.

Afiliación

Ni WJ; Department of Pharmacy, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
Zhou H; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Lu H; Department of Pharmacy, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
Ma NN; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Hou BB; Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Li W; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Kong FX; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Yu JT; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Hou R; Department of Pharmacy, The Second People's Hospital of Hefei, Hefei, Anhui, People's Republic of China.
Jin J; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Wen JG; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Zhang T; Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Meng XM; School of Basic Medicine, Anhui Medical University, Hefei, Anhui, People's Republic of China.

Clin Transl Med ; 13(8): e1359, 2023 08.

Article en En | MEDLINE | ID: mdl-37537731

Asunto(s)

Metiltransferasas; ARN; Animales; Humanos; Ratones; Fibrosis; Metiltransferasas/genética; Metiltransferasas/metabolismo; Simulación del Acoplamiento Molecular; ARN Mensajero/genética; Proteínas de Unión al ARN

Palabras clave

N6-methyladenosine (m6A); chronic kidney disease; insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2); methyltransferase-like 3 (METTL3); renal fibrosis; traditional Chinese medicine

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: ARN / Metiltransferasas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Transl Med Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google